Actelion Pharmaceuticals US, Inc.

Actelion Pharmaceuticals U.S., Inc. (Actelion) is a biopharmaceutical company. The company principally engaged in research, development, selling and marketing of biopharmaceutical products. The company provides three types biopharmaceutical products namely, tracleer, zavesca, and ventavis. The company announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York heart association class III and IV pulmonary arterial hypertension (PAH). Tracleer was approved in 2001 as the first oral treatment for PAH. Actelion is working as a subsidiary of Actelion, Ltd. The company is headquartered in South San Francisco in California, the US.

Street: 
5000 Shoreline Court
City: 
South San Francisco
Postcode: 
94080
Federal State : 
United States
WebSite: 
www.4ventavis.com
Fax: 
1-650-589 1501

Company Index Score

Current Index Score Historical Index Score
  • Actelion Pharmaceuticals US, Inc. currently scores 50 % in the index.
  • Actelion Pharmaceuticals US, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Actelion Pharmaceuticals US, Inc. is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets